By Karen Roman
Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells.
The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated in a press release.
Register for our weekly newsletter HERE
“Following our successful listing on NASDAQ earlier this month, the BIO International Convention presents a great opportunity and is the ideal timing to provide more details on how our BiTAC-ADC platform can be applied to the potential benefit of cancer patients,” said Heinz Schwer, Ph.D., MBA, VERAXA Chief Business Officer.
READ MORE
Aurora Cannabis Generates 55% Revenue Outside Canada as Medical Sales Surge – Quarterly Update Report
Contact:
Click HERE to follow us on LinkedIn
